Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 12/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL246439 | 0.86 | PIK3CA (0.50) | PIK3CAL3MBTL1HSD17B10LMNAALOX5AP | |
| SCHEMBL245528 | 0.86 | PIK3CA (0.50) | PIK3CAL3MBTL1HSD17B10P2RX7LMNA | |
| SCHEMBL245506 | 0.82 | PIK3CA (0.51) | PIK3CAL3MBTL1HSD17B10PARP1 | |
| SCHEMBL248997 | 0.82 | PIK3CA (0.51) | PIK3CAL3MBTL1HSD17B10LMNAPARP1 | |
| SCHEMBL247622 | 0.78 | PIK3CA (0.48) | PIK3CALMNA | |
| SCHEMBL2712435 | 0.73 | PIK3CA (0.43) | PIK3CAPARP1 | |
| SCHEMBL2713627 | 0.72 | PIK3CA (0.38) | PIK3CA | |
| SCHEMBL2123588 | 0.71 | PIK3CA (0.49) | PIK3CAL3MBTL1P2RX7LMNATP53 | |
| SCHEMBL248229 | 0.71 | PIK3CA (0.51) | PIK3CA | |
| SCHEMBL2712138 | 0.71 | PIK3CA (0.59) | PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445886-B1 | 4-AMINOQUINOLINE DERIVATIVES AS PI3K INHIBITORS | AMGEN INC (US) | 2016-03-30 | — | — | EP | disclosed |